Vivesto AB at Sachs Associates Biotech in Europe Forum (Virtual) Transcript
Good morning, everyone. My name is Francois Martelet. I'm the CEO of Oasmia. Delighted to be here with you. I'm going to provide you an update on our company's business, Oasmia.
Oasmia is not, as you may expect, a drug delivery company, but we are an innovation focused, fully integrated specialty pharma company. We are using a technology platform in order to either reformulate existing compounds that are not water soluble or to create new compounds. And we have a portfolio in human health as well as in animal health. We have a lead product approved called Apealea, approved in Europe for advanced ovarian cancer. We have signed off a partnership with a US-based company.
We are listed on the Stockholm Stock Exchange with a market cap of around SEK2 billion. As I said earlier, we are really an R&D certified production facility and R&D lab testing integrated as well. I've been join the company in March of this year.
Building a sustainable, profitable specialty pharma company is our goal. And how do we do that?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |